Figure 2.

SGLT2 Inhibitors Versus GLP-1RAs on Cardiovascular Outcomes

The bars represent absolute effects of treatment per 1,000 patients treated for 5 years for patients at very low risk (no cardiovascular risk factors), low risk (3 or more cardiovascular risk factors), moderate risk (atherosclerotic cardiovascular disease), high risk (chronic kidney disease), and very high risk (atherosclerotic vascular disease plus chronic kidney disease). (A) All-cause death: SGLT2 inhibitor and GLP-1RA compared with placebo. (B) All-cause death: SGLT2 inhibitor compared with GLP-1RA. (C) Cardiovascular death: SGLT2 inhibitor and GLP-1RA compared with placebo. (D) Nonfatal myocardial infarction: SGLT2 inhibitor and GLP-1RA compared with placebo. (E) Nonfatal stroke: SGLT2 inhibitor and GLP-1RA compared with placebo. (F) Nonfatal stroke: SGLT2 inhibitor compared with GLP-1RA. Adapted from Palmer et al (27) with permission. ARR = absolute risk reduction; other abbreviations as in Figure 1.